Skip to content

Contact Us

Contact Us

Ovarian Cancer Research Alliance

Mailing Address
45 Rockefeller Plaza, 20th Floor, New York, NY 10111
212-268-1002

Washington DC Office
1101 14th Street NW, Suite 850, Washington, DC 20005
866-399-6262 (Toll Free) | 202-331-2292 (Fax)

info@ocrahope.org

Donations

Make an online donation today.

Mail your contributions to the address below:

Ovarian Cancer Research Alliance
Post Office Box 32141
New York, NY 10087-2141

Tax ID #13-3806788

Patient Support Line

We’re here for you! Our Patient Support team is available to take your calls Monday – Friday. Call 212-268-1002 and if no one is available when you call, someone will get back to you within 24 hours.

Press

For all press inquiries, please contact:

Amanita Duga-Carroll

ADC Strategic Communications, Inc.

917-597-7880
adcstrategiccomms@gmail.com

Related Topics

The Overview: August 2026

The Overview: August 2026

September is Ovarian and Gynecologic Cancer Awareness Month—a time for our community to unite, raise awareness, and push forward in the search for better treatments and cures. This year, that push forward took a major step. In May, we launched the Research Exchange, a new kind of online community that represents a fundamental shift in how … Continued

Read more

The FDA Wants to Hear From You at OCRA’s Online Conference

The FDA Wants to Hear From You at OCRA’s Online Conference

Submit Your Questions for the FDA Listening Session On September 16–17, Ovarian Cancer Research Alliance (OCRA) will host the International Gynecologic Cancer Conference®, the largest conference dedicated to the gynecologic cancer community. Day 2 features a special opportunity: a Listening Session with leaders from the U.S. Food and Drug Administration (FDA). Ask questions about the FDA’s … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.